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Complications of Percutaneous Endoscopic Gastrostomy in Dogs and
Cats Receiving Corticosteroid Treatment
J. Aguiar, Y.M. Chang, and O.A. Garden
Background: Corticosteroid treatment is commonly required in veterinary patients for treatment of inflammatory,
immune-mediated, neurologic, and neoplastic diseases, which also may require assisted enteral nutrition via percutaneous
endoscopic gastrostomy (PEG).
Objective: To evaluate complications associated with PEG use in dogs and cats receiving corticosteroid treatment.
Animals: Forty-two animals were included in the study: 12 dogs and 2 cats in the steroid group and 26 dogs and 2 cats in
the control group.
Methods: Medical records, between January 2006 and March 2015, were reviewed. Patients were included if the PEG tube
was in use for at least 24 hours and if complete medical records were available. Patients were assigned to the control group if
they were not treated with corticosteroids during PEG use or to the steroid group if they had received corticosteroids during
PEG tube use. Complications were classified as minor, moderate, and major in severity. Maximum severity complication rate
was compared between groups.
Results: The general prevalence of complications was found to be similar between groups (P = .306), but in the steroid
group, 43% of the cases developed a major severity complication compared with 18% of the control group (P = .054).
Conclusion and Clinical Importance: Owners of dogs and cats receiving corticosteroids, in which PEG is planned, should
be counseled about possible complications beyond those associated with PEG tube usage alone.
Key words: Complications; Corticosteroids; Enteral nutrition; Percutaneous endoscopic gastrostomy tube.
Percutaneous endoscopic gastrostomy (PEG) wasfirst performed in 1979 in a pediatric hospital in
Ohio, and it was described in the veterinary field in
1986.1–3 Today, PEG tube placement is considered the
preferred route to provide long-term enteral care for
patients that are unable to swallow or have neurologic
disorders.4–6
In 1990, the technique of PEG tube placement was
evaluated in veterinary medicine in 54 dogs and cats,
and in 2006, complications associated with PEG tubes
were compared with those associated with surgical gas-
trostomy in dogs and cats7. Indications for PEG tube
placement included hepatic, oronasal, and esophageal
disease; cranial nerve deficits; cranial and tracheal sur-
gery; chronic kidney disease; pancreatitis; vestibular dis-
ease; and various neoplastic conditions.7,8
Although PEG tube placement is considered a safe
technique, many studies in human and veterinary medi-
cine have identified several complications associated
with this procedure.8,9 In a comprehensive clinical
literature review, the main complications associated
with PEG tube placement in humans between 1980 and
2013, were wound infection, inadvertent PEG tube
removal, tube blockage, pneumoperitoneum, gastric
outlet obstruction, peritonitis, aspiration pneumonia,
hemorrhage, buried bumper syndrome, bowel perfora-
tion, necrotizing fasciitis, and metastatic seeding.10 In
veterinary medicine, a few studies have reported compli-
cations associated with the placement and management
of PEG tubes in dogs and cats.7,8 The most common
complications encountered include stoma site inflamma-
tion and infection, pneumoperitoneum, gastric bleeding
from the PEG site, splenic or hepatic laceration, vomit-
ing, inadequate gastric emptying, aspiration pneumonia,
septic peritonitis, tube dislodgement, tube removal, and
fistula formation.7,8
Corticosteroid treatment is commonly required in
human and veterinary patients, also requiring assisted
enteral nutrition via a PEG tube for the treatment of
various inflammatory, immune-mediated, neurologic,
and neoplastic conditions.11,12 Corticosteroids impact
several steps of the wound-healing process by decreas-
ing the expression of cytokines and therefore suppress-
ing the inflammatory process, attenuating fibroblast
proliferation, impairing wound re-epithelialization, and
decreasing the stretch ability of the scar.13
In 2009, the safety of PEG tubes in human patients
receiving corticosteroids was investigated, and it was
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concluded that this technique was not associated with
an increased complication rate in patients receiving
acute or chronic corticosteroid treatment.14 To the
authors’ knowledge, no studies have investigated the
effect of corticosteroid treatment in veterinary patients
concomitantly receiving enteral feeding by means of a
PEG tube, and this, therefore, was the objective of this
study.
Materials and Methods
Case Selection
Medical records from dogs and cats that had PEG performed
at a small animal referral teaching hospital between January 2006
and March 2015 were reviewed for this retrospective study. To be
included in the study, animals must have had the PEG tube in
place for at least 24 hours and complete medical records, including
clinical notes from referring veterinarians, kennel sheets, communi-
cation records with patients’ owners, and notes from PEG tube
removal, had to be available.
Cases were assigned to 1 of the following groups: (1) steroid
group and (2) control group. To be included in the steroid group,
animals had to have received prednisolone, or an equivalent corti-
costeroid drug, at a dosage ≥1 mg/kg/day. All cases included in
the steroid group received corticosteroids for at least 50% of the
time of PEG tube use. To be included in the control group,
corticosteroids could not have been given up to 48 hours before,
during PEG tube placement, or during the time of PEG tube use.
Data regarding signalment, year of tube placement, history
(including medications before referral), physical examination
(including body weight and body condition score [BCS] 1–9), indi-
cation for PEG tube placement, treatment, complications associ-
ated with PEG, and length of tube use were recorded.
Percutaneous endoscopic gastrostomy was performed using a
Fresenius Kabi tube.a All animals had PEG performed by a
board-certified internist or resident supervised by a board-certified
internist. The PEG tube placement was performed in a standard
fashion as described previously.8
All PEG tubes were used for feeding, which started within the
first 12–24 hours after tube placement. Frequency of tube use for
feeding was dependent on clinicians’ preferences and varied from
case to case.
The PEG tube site was checked and aseptically dressed at least
once daily during tube use. During hospitalization, notes were
made after each change of dressing. Complications that may have
occurred after discharge were documented in the communication
records with owners and referring veterinarians.
Complications associated with PEG tube placement and use
were categorized into 3 severity categories: minor, moderate, and
major. Complications were considered of minor severity if they
required minimal or no veterinary intervention. Complications
were considered of moderate severity if they required veterinary
intervention but did not put patients’ lives at risk. Complications
were classified as major severity if they required immediate veteri-
nary intervention and could have put patients’ lives at risk. Inflam-
mation of the stoma site, PEG tube blockage, and serous
discharge were classified as minor severity complications. Develop-
ment of sanguineous discharge, abdominal pain around the stoma
site, and chewing of the tube at its tip were considered of moder-
ate severity. Development of purulent discharge around stoma site,
PEG tube dislodgement, and chewing of the tube at the stoma site
were considered major severity complications.
Stoma site infection was defined by the development of purulent
discharge at the stoma site. Culture and sensitivity results were
noted if available.
Statistical Analysis
Clinical variables were assessed for normality by visual inspec-
tion of histograms and use of the Shapiro-Wilk test. Continuous
nonnormally distributed variables (age, year of tube placement,
body weight, duration of PEG tube use, time of occurrence of
maximum severity complication) were compared between groups
using the Mann-Whitney U-test and Kruskal-Wallis test, and non-
normally distributed categorical variables (body condition score,
sex, and development of complications) were compared between
groups using the Pearson chi-square and Fisher’s exact test. Maxi-
mum complication rate was compared between groups using Ken-
dall’s tau-c. Results are presented as median and interquartile
range (IQR), unless otherwise stated. Differences in P < .05 were
considered statistically significant. Statistical analysis was per-
formed using commercially available software.b ,c
Results
A total of 38 dogs and 4 cats met the inclusion crite-
ria for this study. Twelve dogs and 2 cats were included
in the steroid group, and 26 dogs and 2 cats were
included in the control group.
The 2 groups were only statistically different regard-
ing the duration of PEG tube use (P = .043), with the
PEG tube being in use for a longer time period in the
steroid group (Table 1). However, when the time of
occurrence of the maximum severity complications was
Table 1. Comparison between control and steroid
group regarding sex, age, year, body weight, and body
condition score at placement of the PEG tube and
length of PEG tube use.
Variable Control Group Steroid Group P Value
Sex Entire male (n = 6);
neutered male (16);
entire female (4);
neutered female (5)
Entire male (n = 6);
neutered male (1);
entire female (1);
neutered female (6)
0.005a
Variable
Control Group,
Median (25th
Percentile–75th
Percentile)
Steroid Group,
Median (25th
Percentile–75th
Percentile)
P
Value
Age at placement
of PEG tube
(years)
5.2 (1.7–9.7) 5.35 (3.5–8) 1b
Year of placement
of PEG tube
2010 (2007–2013) 2009 (2007–2012) 0.468b
Body weight at
placement of
PEG tube (kg)
18.2 (7.0–29.5) 31.5 (5.7–36.9) 0.198b
BCS at placement
of PEG tube
(1–9)
4 (3–4) 4 (3–5) 0.745a
Length of PEG
tube use (days)
13.5 (2.2–27.7) 24.5 (8.2–95.2) 0.043b
n, number of cases; BCS, body condition score; PEG, percuta-
neous endoscopic gastrostomy.
aPearson chi-square.
bMann-Whitney U-test, significant difference between groups
(P ≤ .05).
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compared between groups, no difference was found
(P = .368; Fig 1).
Sex distribution also was found to be dissimilar
between groups (P = .005). In the control group, 16
(57%) animals were neutered males, 5 animals (18%)
were neutered females, 4 (14%) were intact females, and
3 (11%) were intact males. In the steroid group, 6 ani-
mals (43%) were entire males, 6 (43%) were neutered
females, 1 (7%) was an intact female, and 1 (7%) was a
neutered male. However, no specific sex category was
found to be more predisposed for the development of
complications (P = .797).
In the steroid group, cases received either pred-
nisolone or dexamethasone. Dexamethasone dosages
ranged from 0.15 to 0.5 mg/kg/day, whereas pred-
nisolone dosages ranged from 1 to 4 mg/kg/day. Dura-
tion of corticosteroid administration ranged from 1 to
172 days.
Reasons for placement of the PEG tube in the steroid
group included meningitis, mast cell tumor, esophageal
dysmotility, esophageal stricture, oropharyngeal vasculi-
tis (drug reaction), immune-mediated polyarthritis,
cricopharyngeal dysphagia, lymphangiectasia, inflamma-
tory bowel disease, and feline dysautonomia.
Regarding reasons for placement of the PEG tube, 24
of the 42 animals (57%) had gastrointestinal disease, 5
(12%) had neurologic conditions, 4 (10%) had inflam-
matory or infectious diseases, 3 (7%) had neoplastic
conditions, 3 (7%) had renal disease, and the 3 (7%)
had immune-mediated conditions (Table 2).
The PEG tube complications identified in the study
population included serous discharge (n = 17), inflam-
mation of the stoma site (8), sanguineous discharge (7),
purulent discharge (7), PEG tube dislodgement (6),
stoma site pain (4), tube chewed at the tip (3), PEG
tube blockage (2), and tube chewed at the stoma site
(1). Complications were classified according to their
severity. Inflammation of the stoma site, PEG tube
blockage, and serous discharge were classified as minor
severity complications. Development of sanguineous
discharge, abdominal pain around the stoma site, and
tube chewed at its tip were considered of moderate
severity. Development of purulent discharge around
stoma site, PEG tube dislodgement, and tube chewed
at the stoma site were considered major severity
complications.
Of the patients included in the study, 15 (36%) had
no complications, 8 (19%) developed at least a minor
severity complication, 8 (19%) developed at least 1
moderate severity complication, and 11 (26%) devel-
oped at least 1 major severity complication. In the con-
trol group, 16 (57%) of the 28 patients developed
complications, whereas in the steroid group, 11 (78%)
of the 14 patients developed a complication.
No association was found between the development
of different severity of complications and the BCS of
the animals at the time of PEG placement (P = .164).
Similarly, no association was found between the body
weight of the animals at the time of placement of the
PEG tube and subsequent development of different
severity complications (P = .136).
The general prevalence of complications was found to
be similar between groups (P = .306), but in the steroid
group, 43% of the patients developed a major severity
Fig 1. Time of development of maximum severity complications
in the steroid and control groups; dots refer to each case of the
control and steroid group that developed complications.
Table 2. Indications for placement of the PEG tube in
the study population.
Indications for Placement of PEG Tubes No. of Cases
Gastrointestinal diseases
Gastrointestinal ulceration 3
Esophageal stricture 3
Pharyngeal dysphagia 3
Megaesophagus 3
Pancreatitis 2
Esophagitis 2
Inflammatory bowel disease (IBD) 2
Oropharyngeal achalasia 1
Esophageal dysmotility 1
Oropharyngeal inflammation 1
Lymphangiectasia 1
Acute gastritis 1
Primary ileus 1
Neurologic diseases
Dysautonomia 3
Meningitis 1
Trigeminal neuropathy 1
Neoplasia
Gastrointestinal mast cell tumor 1
Colorectal adenocarcinoma 1
Duodenal lymphoma 1
Renal disease
Acute kidney disease 3
Inflammatory/infectious
SIRS 2
Tetanus 2
Immune-mediated diseases
IMPA 2
Myasthenia gravis 1
SIRS, systemic inflammatory response syndrome; IMPA,
immune-mediated polyarthritis; PEG, percutaneous endoscopic
gastrostomy.
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complication compared with 18% of the control group
(P = .054, Fig 2).
In the study population, the general prevalence of
stoma site infection and PEG tube dislodgement were
17% and 12%, respectively. No statistically significant
difference was found between groups in terms of stoma
site infection rate (P = .56, Fig 3), with 4 (14%) ani-
mals in the control group and 3 (21%) animals in the
steroid group having infections of the stoma site. Cul-
ture and sensitivity results were available for 2 cases.
Klebsiella sp. sensitive to all antibiotics and Enterococ-
cus sp. only sensitive to fluoroquinolones were cultured
from 1 dog, which developed a purulent discharge of
the stoma site on day 7 after placement of the PEG
tube. The other dog, which experienced purulent dis-
charge around the stoma site, yielded a profuse marked
E. coli, Streptococcus sp., and Enterococcus sp. sensitive
to the majority of antibiotics tested. In terms of occur-
rence of PEG tube dislodgement, no difference was
found between groups (P = .736, Fig 4), with 11% of
patients in the control group and 14% of patients in
the steroid group experiencing tube dislodgement.
Discussion
To the authors’ knowledge, ours is the first study
evaluating the effects of corticosteroid treatment on the
development of complications in veterinary patients
with PEG tubes used for enteral nutrition. We were not
able to identify a statistically significant difference
between control and steroid groups regarding the devel-
opment of complications, but we found the develop-
ment of more major severity complications in the
steroid than in the control group. A sample size calcula-
tion indicated that we would have required 76 cases in
the control group and 38 cases in the steroid group in
order to have 80% power to detect a difference between
groups in the occurrence of complications, with a signif-
icance level of .05. Therefore, it is possible that we were
not able to identify a clear difference between groups
given the lack of power.
The 2 groups were statistically different regarding the
duration of PEG tube use. However, when the time of
occurrence of maximum severity complications was
compared between groups, no difference was found.
However, variable length of time of PEG tube use in
the study population is 1 of the limitations of our
study, and some patients may not have had time for
development of complications and others may have had
sufficient time to experience many complications. A
prospective, randomized clinical trial in which the
length of tube use would be the same between groups
would avoid this confounding factor, but would be
impracticable and unethical in a clinical setting.
The most common indications for placement of a
PEG tube in this study were gastrointestinal disease,
dysautonomia, and acute kidney disease, and these rea-
sons were similar to those described in previous stud-
ies.7,8 The complications associated with the PEG tube
use encountered in our study also were similar to those
Fig 2. Comparison of different severity complications between
groups; the number of cases is indicated in each bar.
Fig 3. Comparison of stoma site infections between groups; the
number of cases is indicated in each bar.
Fig 4. Comparison of percutaneous endoscopic gastrostomy tube
dislodgement between groups; the number of cases is indicated in
each bar.
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reported in previous studies, such as stoma site
inflammation and infection, tube dislodgement, and
tube removal.7,8,15,16 The most common complication
associated with PEG tube use in our study population
was development of serous discharge, a minor severity
complication, that in most of the cases was found to be
self-limiting after a few sterile dressing changes.
Infection of the stoma site and tube dislodgement
were relatively common complications in the study pop-
ulation. The prevalence of stoma site infection reached
17%, which is similar to the prevalence described in
human patients (5–25%), where the current recommen-
dation regarding antibiotic prophylaxis is the IV admin-
istration of a single dose of cephalosporin in the first
hour after PEG tube placement.10,17 A recent study in
human patients explored the option of giving a single
dose of co-trimoxazole by the PEG tube shortly after
its placement, comparing it to a single IV dose cepha-
losporin, and there was no significant difference between
the infection rates in both groups.18 The cases included
in our study were given cefuroxime or other broad-
spectrum antibiotic IV, which had been administered as
part of treatment of their underlying medical condition.
Higher prevalence of stoma site infections has been
reported in dogs and cats with renal failure and was
attributed to increased susceptibility to infection and
delayed wound healing, associated with uremia and
malnutrition.19 Similarly, in the study population, the
administration of immunosuppressive dosages of ster-
oids could have precipitated the development of stoma
site infections. The comparison of stoma site infection
rate between groups, however, yielded no significant dif-
ference between groups.
Tube dislodgement occurs when the apposition
between the gastric and abdominal wall is not ideal and
the PEG tube is able to move in an out through the
stoma site, increasing the risk for development of septic
peritonitis if the gastric contents reach the peritoneal
cavity.9,10 In this study, PEG tube dislodgement
occurred in 12% of cases, which is similar to the preva-
lence reported in human medicine (up to 13% of
patients).10 The PEG tube stoma and adhesions
between the gastric and abdominal wall begin to mature
approximately 7–10 days after tube placement, and this
process can take up to 1 month in malnourished and
immunosuppressed patients.9 Therefore, the comparison
of PEG tube dislodgement rate between the control and
steroid groups yielded no significant difference between
groups.
Sanguineous discharge was present in 7 of the
patients and pressure bandages were required to stop
the hemorrhage. In human medicine, it is recommended
to tighten the clip at the stoma site to produce compres-
sion of the gastric wall against the abdominal wall for
up to 48 hours.9 Retroperitoneal bleeding is possible in
these cases, and monitoring for this complication also is
usually recommended in human patients.10
Other complications previously described, such as
pneumoperitoneum, gastric bleeding from the PEG site,
splenic or hepatic laceration, vomiting, inadequate gas-
tric emptying, aspiration pneumonia, and fistula
formation, were not found in this study population.7,8
However, imaging studies were not performed in every
case to check for the presence of pneumoperitoneum,
and it is, therefore, possible we may have missed the
development of this complication. In human medicine,
the development of pneumoperitoneum after the place-
ment of a PEG tube is estimated to happen in 50% of
the patients and usually is considered self-limiting.9
A recent review of the effects of corticosteroids on
wound healing concluded that administration of high
doses of corticosteroids (equivalent to 1.5 mg/kg of
prednisolone) for 10 days had no clinical impact on
wound healing, but treatment for at least 30 days
before surgery could increase the complication rate up
2- to 5-fold.13 In this study, animals included in the
steroid group received prednisolone, or an equivalent
corticosteroid drug, at a dosage ≥1 mg/kg/day for at
least 50% of the time the PEG tube was in use.
However, given the retrospective nature of our study,
we included animals that received corticosteroids at
different dosages and frequencies of administration,
for a variable length of time and at different
stages of PEG tube use. Therefore, it is possible that
these differences may have affected the results
obtained.
The limitations of our study are related to its retro-
spective nature and the fact that it was highly depen-
dent on the quality of the information recorded by
clinicians, nurses, and referring veterinarians. Further-
more, no specific protocol for placement and manage-
ment of PEG tubes was used, even if the same brand of
PEG tube was used throughout the study period. A
prospective trial would have been ideal to avoid the
introduction of some of the confounding factors of this
study. However, in a clinical setting, it would have been
unethical to randomize patients to steroid treatment or
no steroid treatment because the primary goal was to
treat patients’ underlying conditions and nutrition was
a secondary goal. However, different conditions require
different corticosteroid protocols and each treatment
plan should be adjusted to patient’s needs, based on
response to treatment and development of adverse
effects. Owners of animals receiving corticosteroids in
which PEG is planned should be appraised of possible
complications beyond those normally associated with
PEG tube usage alone.
Footnotes
a Freka PEG Fresenius Kabi; Cheshire, UK
b SPSS 22; IBM, Armonk, NY
c GraphPad Prism 6; Software, La Jolla, CA
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